Nov 25, 2016 7:00am EST Can-Fite Reports Financial Results for Nine Months Ended September 30, 2016 & Provides Clinical Update
Nov 16, 2016 7:00am EST American Medical Association's USAN & World Health Organization's INN Approve "Namodenoson" as Generic Name for Can-Fite's Liver Drug CF102
Nov 09, 2016 7:00am EST Can-Fite Receives Notice of Allowance From U.S. Patent and Trademark Office for Erectile Dysfunction Drug
Nov 07, 2016 7:00am EST Can-Fite to Participate in BIO-Europe Partnering Conference on November 7-9, 2016 in Cologne, Germany
Nov 01, 2016 7:00am EDT Can-Fite Advances Towards a Pivotal Phase III Clinical Trial in Psoriasis with Piclidenoson (CF101) Following Reaching Agreement with EMA
Oct 13, 2016 7:00am EDT Can-Fite Submits Protocol for Phase II Trial of CF102 in the Treatment of NAFLD/NASH
Sep 20, 2016 7:00am EDT Can-Fite Reports New Data on CF102's Liver Protective & Regenerative Properties Published in Scientific Journal
Sep 13, 2016 7:00am EDT Can-Fite Receives Notice of Allowance for Psoriasis Patent in Europe Ahead of Phase III Trial
Sep 07, 2016 7:00am EDT Can-Fite to Present at Rodman & Renshaw Conference in New York City on September 12, 2016
